Epigenomics
The Tennessee-based firm is combining molecular and protein testing technologies that it brought under one roof in a pair of deals last summer.
In Brief This Week: Enzo Biochem, Epigenomics, Co-Diagnostics, Lunit, COLA, More
News items for the week of March 11, 2024.
The company recently published data demonstrating its platform's potential use for prediction and monitoring of immunotherapy response for patients with lung cancer.
Trial Failure Raises Questions About MRD Testing Utility, but Prognostic Evidence Remains Strong
Presentations at last week's ASCO GI meeting highlighted the ongoing generation of promising data for ctDNA-based minimal residual disease testing despite recent missteps.
Precede Biosciences Debuts Chromatin-Based Liquid Biopsy Platform Backed by New Data at ESMO
Premium
The firm has begun working with pharma, using its technology to identify and monitor transcriptionally regulated drug targets. It is also eyeing multiple clinical diagnostic applications.